LUMO: Lumos Pharma, Inc. Stock

by  •  • Comments Off on LUMO: Lumos Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 37.54
Enterprise Value ($M) 24.02
Book Value ($M) 4.91
Book Value / Share 0.57
Price / Book 7.64
NCAV ($M) 4.73
NCAV / Share 0.55
Price / NCAV 7.94

Profitability (mra)
Return on Invested Capital (ROIC) -6.87
Return on Assets (ROA) -0.73
Return on Equity (ROE) -0.98

Liquidity (mrq)
Quick Ratio 2.66
Current Ratio 2.66

Balance Sheet (mrq) ($M)
Current Assets 17.27
Assets 17.46
Liabilities 12.55
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
7 days ago 13G Private Advisor Group, LLC 9.16
02-09 13G/A Goldman Sachs Group Inc 5.10 -13.36
02-06 13G Wells Fargo & Company/mn 5.30
11-29 13D/A Blackstone Holdings II L.P. 4.90 -17.61

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2024. ☐ Transition report pursua
2024-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2024. ☐ Transition report pursuant to
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2024. ☐ Transition report pursuant t
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-18 3,066 74,073 4.14
2024-11-15 7,691 101,552 7.57
2024-11-14 857 22,522 3.81
2024-11-13 5,996 96,096 6.24

(click for more detail)

Similar Companies
LGND – Ligand Pharmaceuticals Incorporated LNTH – Lantheus Holdings, Inc.
LRMR – Larimar Therapeutics, Inc. LXEO – Lexeo Therapeutics, Inc.
MDWD – MediWound Ltd.


Financial data and stock pages provided by
Fintel.io